Healhty

Balance is the ability of an individual to maintain posture against gravity and sustain stability during movement; it depends on the coordinated functioning of the proprioceptive, visual, and vestibular systems, as well as the central nervous system. Current studies show that movement control occurs not only through the motor system but also through the interaction of sensory-cognitive-motor components. Cognitive functions encompass processes such as attention, memory, visuospatial skills, and executive functions, with attention and visuospatial processing playing a particularly important role in balance control. The literature reports significant relationships between balance and cognitive functions, particularly noting that increased attention requirements in dual-tasking situations negatively impact balance performance. Furthermore, it has been shown that both balance performance and cognitive functions are affected by circadian rhythm and chronotype, with individuals exhibiting different performance levels at different times of the day. Despite this, studies examining the relationship between balance and cognitive functions appear to have insufficiently addressed the chronotype factor. Therefore, the aim of this study is to investigate how the relationship between balance and cognitive functions changes according to individuals' chronotypes.

The goal of this clinical trial is to learn how 24 IU oxytocin (OT) and 24 IU arginine vasopressin (AVP), administered through the oral mucosa, affect attention to emotional faces and related brain activity in healthy adults. The study will compare OT and AVP with a placebo (PLC). The main questions it aims to answer are: 1. Does oromucosally administered oxytocin produce a behavioral pattern of modulation of top-down and bottom-up attention to emotional faces that is qualitatively consistent with previously reported intranasal oxytocin effects, and how does this pattern compare with that produced by arginine vasopressin? 2. Do oromucosally administered oxytocin and arginine vasopressin modulate neural responses within predefined brain regions and networks involved in emotional salience, attentional control, and social information processing, and are these neural effects consistent with their behavioral effects? 3. Do oxytocin and arginine vasopressin show overlapping or distinct patterns of neural modulation across top-down and bottom-up attention and high and low attentional load conditions? Researchers will compare 24 IU OT and 24 IU AVP with a placebo to determine how these treatments influence emotional face attention and brain activity. Participants will: * Receive 24 IU OT, 24 IU AVP, or placebo via a lyophilized oromucosal lollipop * Allow the treatment to be absorbed through the oral mucosa for about 5 minutes * Provide blood samples before and after treatment to assess peripheral oxytocin and vasopressin levels * Complete emotional face attention tasks during fMRI scanning * Have response time, response accuracy, brain activity, and peripheral neuropeptide levels measured * Complete questionnaires assessing mood states and personality traits before treatment administration to control for potential confounding effects

Background: Childhood obesity is a multifactorial health condition associated with profound metabolic, psychosocial, and socioeconomic ramifications across the lifespan. Among eating behaviors associated with obesity, limited attention has been given to chewing and food texture as pathways that may influence energy intake and weight regulation. Existing pediatric research remains scarce, methodologically heterogeneous, and often inconclusive. Aims: This study aims to examine associations between oral processing behaviors during a standardized meal, including eating duration, eating rate, Ghrelin levels, and anthropometric measures in healthy children. Methods: Participants responding to public advertisements will be screened for eligibility, including age (6-11 years), health status, absence of food allergies or intolerances, dental or developmental problems, and measured weight and height to achieve a sample of 40 children with obesity and 40 with normal weight. In a randomized crossover design, participants will consume two isocaloric, non-processed test meals differing in food texture (soft vs. hard) during separate laboratory visits. Eating behavior will be objectively assessed using a Universal Eating Monitor with synchronized video analysis to quantify chewing time, number of chews, and eating rate. Salivary ghrelin, subjective satiety (measured using visual analog scales), and total daily energy intake (assessed via 24-hour dietary recall) will be evaluated, along with anthropometric, body composition, strength measures, and sociodemographic and behavioral data. To account for familial and shared environmental influences on eating behavior, at least one parent will undergo a parallel assessment, conducted separately from the participating child. Participants will receive a modest shopping voucher to facilitate retention. Associations between oral processing behaviors, physiological responses, and weight status will be examined using multivariable regression models. Exploratory mediation analyses will be conducted to assess whether ghrelin and satiety responses partially account for the observed associations.

In this study, 4 dose groups are planned: Group 1 (0.22 mg, QD), Group 2 (0.22 mg, BID), Group 3 (0.44 mg, QD), and Group 4 (0.44 mg, BID). Ten healthy study participants will be enrolled in each dose group, and randomized to the investigational drug group or the placebo group in a 4:1 ratio (i.e., 8 study participants in the investigational drug group and 2 study participants in the placebo group). An appropriate gender ratio will be ensured within each dose group.

In France, over 1.5 million people suffer from mild cognitive impairment, often a precursor to Alzheimer's disease (AD), whose global prevalence could reach 153 million by 2050. With no curative treatment available, maintaining patients' autonomy at home is essential to mitigate the negative effects of institutionalization and reduce economic costs. Non-pharmacological approaches, such as cognitive training, have shown potential in stabilizing cognitive functions. Research suggests that motor networks and procedural memory remain relatively preserved in early AD, and bodily engagement during encoding enhances memory. For patients with motor impairments, motor imagery (MI) activates these networks without actual movement. Additionally, dynamic visual cues, like videos, reduce cognitive load compared to static images. This project aims to combine real action, MI, and dynamic visual supports to optimize memory. By validating 120 videos of daily activities, it will assess the impact of action on recall, evaluate MI's effectiveness for patients with mobility limitations, and confirm the superiority of videos over static images. The results could support the development of digital tools, such as serious games, to enhance patients' autonomy and address aging-related challenges.

The aim of this observational study is to investigate the impact of body composition on the absorption, distribution, and metabolism of drugs. The primary question it seeks to answer is: Does body composition affect the absorption, distribution, and metabolism of drugs? By combining pharmacokinetic parameters and adverse drug reactions, the study will analyze differences in the metabolism of drugs under various body composition conditions. During the Phase I clinical trial, under the guidance of the researchers, subjects will use the non-invasive InBody S10 body composition analyzer to obtain body composition data, including but not limited to inorganic salts, muscle mass, lean body mass, body weight, and body fat percentage.

This is a single-center, random, double blind, placebo control clinical study to evaluate the safety, tolerability pharmacokinetics and food effect of HSK55879 in healthy subjects

A randomized, double-blinded, partial-open, placebo/active-controlled, single/multiple dosing, dose escalation phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of IY-828026 in healthy adult volunteers

This quasi-experimental study aims to evaluate the effects of mechanical vibration applied to the pelvic floor musculature in healthy women aged 18-45. The intervention involves vibrational therapy targeting the central fibrous nucleus of the perineum, with the goal of assessing changes in muscle tone, strength, and biomechanical properties. The study will also examine the tolerance to this technique, with data collected at baseline and after 8 weeks of treatment.

This study investigates whether MDMA may have a pain-reducing effect. The effect of MDMA is compared with a placebo (a substance with no active effect). In the study, moderate pain will be artificially created in healthy participants using repeated small electrical pulses applied under the skin. At the same time, participants will take MDMA or a placebo by mouth. This allows researchers to compare how MDMA affects the artificially created pain. A total of 20 healthy volunteers will take part in this study.

The primary objective of this study is to investigate the acute physiological and metabolic effects of ingesting the short-chain fatty acids (SCFA)s propionate (three carbon atoms long; C3:0) and butyrate (C4:0) in healthy men and women. This aim will be addressed through a block-randomized cross-over study including two visits with acute intake of propionate and butyrate, respectively. The hypothesis is that plasma ketone body levels will increase during the first three hours after intake of butyrate, but not propionate, in healthy individuals in the overnight fasted state.

The purpose of this clinical trial is to investigate the effects of a rehabilitative game-based intervention on self-efficacy, balance, and visual-motor integration in individuals aged 60 years and older. The primary research questions are: Does the rehabilitative game-based intervention improve balance and visual-motor integration? Does the rehabilitative game-based intervention improve self-efficacy levels? Researchers will compare a rehabilitative game intervention group with a control group. Participants will complete baseline and post-intervention assessments. Individuals in the intervention group will participate in rehabilitative game sessions twice per week for 6 weeks, while the control group will not receive any intervention.

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence. It causes irreversible central vision loss and significant difficulties in daily activities, impairing patients' quality of life and independence. Conventional clinical assessments, which focus on visual acuity and retinal imaging, do not fully reflect the functional impact of the disease. Virtual reality (VR) makes it possible to create immersive, controlled environments to accurately measure functional vision and simulate real-life situations. The study proposes to develop a standardized and reproducible functional test in virtual reality that can complement conventional examinations and support clinical and industrial research.

This study investigates how the naturally occurring gut hormones GIP and GLP-1 influence whole-body glucose uptake and organ perfusion in humans. Using a state-of-the-art total-body PET-CT scanner, the study measures dynamic uptake of the glucose analogue 18F-FDG and blood flow using H₂¹⁵O across multiple organs during controlled elevations of plasma glucose and endogenous insulin secretion. The project consists of two sub-studies. Sub-study 1 includes healthy individuals who undergo three experimental visits with infusions of GIP, GLP-1, or saline (placebo) during a hyperglycemic clamp followed by FDG PET-CT scanning. Sub-study 2 includes healthy individuals and participants with type 2 diabetes who undergo two experimental visits with saline followed by either GIP or GLP-1 during a hyperglycemic clamp, combined with repeated H₂¹⁵O PET-CT measurements of perfusion. The primary aims are to quantify insulin-mediated skeletal muscle glucose uptake (sub-study 1) and skeletal muscle perfusion (sub-study 2). Secondary aims include assessment of glucose uptake and perfusion across adipose tissue, liver, and additional organs. The results will provide novel physiological insight into postprandial glucose metabolism and serve as reference data for future whole-body PET research.

The goal of this clinical trial is to learn if a Artificial Intelligence integrated Mixed Reality-based High-Alert Medications Management Simulation Program (AIMR-HAM) helps hospital nurses manage high-alert medicines (HAMs) more safely. MR mixes real and virtual elements to let nurses practice in realistic scenarios. The main questions are: Does the AIMR-HAM improve nurses' medication safety skills? Does the AIMR-HAM lower medication errors and improve clinical performance? Researchers will compare two groups to answer these questions: Intervention group: AIMR-HAM Control group: standard education only Who can take part: Nurses who work at large hospitals and have 1 to 6 years of clinical experience. About 60 nurses will join the study. What participants will do: Attend the assigned training (AIMR-HAM or standard education only). Complete short tests and surveys before and after training to measure skills, communication, and clinical reasoning. Report any medication errors that occur during the study. Why this matters: The study will show whether AIMR-HAM training can improve how nurses handle HAMs and make patient care safer.

This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812 following single and multiple SC administrations in normal to overweight or obese but otherwise healthy subjects.

This study is designed as a randomized controlled single-blind experimental study to examine the effectiveness of the oxytocin massage and Marmet technique applied to mothers who have undergone cesarean section on breast milk quantity and maternal state anxiety levels. The hypotheses of the study are as follows: H0.1. There is no difference in the amount of breast milk among mothers in the Marmet technique, oxytocin massage, and control (placebo) groups. H1.1. There is a difference in the amount of breast milk among mothers in the Marmet technique, oxytocin massage, and control (placebo) groups. H0.2. There is no difference in the state anxiety scale scores among mothers in the Marmet technique, oxytocin massage, and control (placebo) groups. H1.2. There is a difference in the state anxiety scale scores among mothers in the Marmet technique, oxytocin massage, and control (placebo) groups. Participants: Marmet technique, oxytocin massage, and control (placebo) groups will be informed about the study and asked to provide their consent. Participants will complete the descriptive questionnaire. Colostrum status will be checked and marked as "present" or "absent" on the "Breast Milk, Vital Signs, and Pain Level Form." Under researcher supervision, the mother will breastfeed her baby. Afterward, the State Anxiety Inventory will be administered. Two hours later, mothers will express milk using a hospital-grade pump, with 15 minutes on each breast (total 30 minutes). Milk volume, vital signs, pain levels, and milk flow rate will be recorded on the relevant form. Following this, mothers in the Marmet group will receive 10 minutes of the Marmet technique, mothers in the oxytocin group will receive 5 minutes of oxytocin massage, and mothers in the control group will receive 5 minutes of light touch on their wrists and shoulders. Immediately after, milk expression will again be performed with 15 minutes per breast (30 minutes total). The State Anxiety Inventory will be re-administered, and milk amount, vital signs, pain levels, and flow rate will be recorded again. All mothers will express milk using a hospital-grade breast pump, and the expression duration is standardized as 15 minutes per breast (30 minutes total) based on the literature. Two expressions will be performed - one before and one immediately after the intervention. Expressed milk will not be discarded and will instead be used to feed the babies via spoon or syringe under the researcher's supervision.

The main aim of the present study is to investigate whether orally (lingual spray) administered oxytocin influences human social attention and behaviors via oxytocin receptors and whether its effects are dose- and task-dependent.